<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685906</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00042</org_study_id>
    <secondary_id>AZD6140/OC Study</secondary_id>
    <nct_id>NCT00685906</nct_id>
  </id_info>
  <brief_title>AZD6140 Oral Contraceptive Interaction Study</brief_title>
  <official_title>A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of co-administration of AZD6140 and
      Nordette® on the blood levels of certain female hormones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels of ethinyl estradiol, a female hormone, following oral administration of AZD6140 and Nordette®</measure>
    <time_frame>At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of various other hormones following concomitant oral administration of AZD6140 and Nordette®</measure>
    <time_frame>At scheduled times following dosing during the first 3 weeks of menstrual cycles 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of AZD6140 and its main metabolite after concomitant oral administration of AZD6140 and Nordette®</measure>
    <time_frame>At scheduled times following dosing during the first 3 weeks of Cycles 1 and 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD6140 when co-administered with Nordette®</measure>
    <time_frame>Screening through completion of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6140</intervention_name>
    <description>90 mg tablet taken by mouth 2 times a day for 21 days per cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel and Ethinyl Estradiol (Nordette®)</intervention_name>
    <description>1 tablet taken by mouth once a day for 28 days per cycle</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Nordette®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females who are healthy, non-pregnant, not planning pregnancy within the study period,
             non-breast-feeding, and pre-menopausal

          -  Either currently taking Nordette® which was well tolerated for at least two months
             prior to randomisation with no history of break-through bleeding, or, willing to take
             Nordette for 2 months prior to receiving the study drug

          -  Females of child-bearing potential must be willing to use at least 1 additional
             medically approved non-hormonal barrier contraceptive method (for example, condom or
             diaphragm) that contains spermicide

        Exclusion Criteria:

          -  History of intolerance (e.g. adverse events) to any oral contraceptive or AZD6140

          -  History of blood vessel or bleeding conditions that would make the volunteer more
             prone to bleeding

          -  History or presence of significant medical problems

          -  Women who are current smokers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audrey , Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SeaView Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>December 1, 2010</last_update_submitted>
  <last_update_submitted_qc>December 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jay Horrow, MD, Medical Science Director, AZD6140</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>oral contraceptive</keyword>
  <keyword>birth control</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

